menu ☰
menu ˟

FDA denies Amneal request to block approvals of generic Forteo

10 Jan 2018
The FDA has rejected Amneal Pharmaceuticals’ citizen petition to refrain from approving any abbreviated new drug applications for generic versions of teriparatide as treatment for osteoporosis.The company, which markets teriparatide under the brand...

Click here to view the full article which appeared in Endocrinology

IPH Logo